Aktienanalyse zu Alexandria Real Estate Equities, Inc (ARE)AREAlexandria Real Estate Equities, Inc

Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry. It operates in the Real Estate sector (REAL ESTATE INVESTMENT TRUSTS industry).

Currently, Alexandria Real Estate Equities Inc (ARE) is not a strong buy. The current price is $43.02, which is below the median analyst price target of $52.50, indicating potential upside. However, the RSI is at 47.099, suggesting a neutral momentum, and the stock has a high forward P/E of 16.6945, which may indicate overvaluation given the company's recent performance. The main risk is the significant decline in stock price over the past year, down 44.75%, reflecting ongoing challenges in the market.

12 analysts cover ARE: 7 rate it Buy, 5 Hold and 0 Sell. The average price target is 56.85.